Drug therapy in the heart transplant recipient - Part III: Common medical problems

Circulation

Volumn 111, Issue 1, 2005, Pages 113-117

  Lindenfeld, JoAnn ^a   Page II, Robert L ^a   Zolty, Ronald ^a   Shakar, Simon F ^a,d   Levi, Marilyn ^b   Lowes, Brian ^a   Wolfel, Eugene E ^a   Miller, Geraldine G ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drugs; Immunology; Rejection; Transplantation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BILE ACID SEQUESTRANT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; LOOP DIURETIC AGENT; METFORMIN; NICOTINIC ACID; PRAVASTATIN; PREDNISONE; RAPAMYCIN; SIMVASTATIN; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TACROLIMUS; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; BONE MARROW SUPPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; FLUID RETENTION; GOUT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCALCIURIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; KIDNEY FAILURE; MYCOSIS; MYOPATHY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; VIRUS INFECTION; WEIGHT GAIN;

ANTI-INFECTIVE AGENTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DEPRESSION; DIABETES MELLITUS; DIPHOSPHONATES; DRUG INTERACTIONS; GOUT; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INFECTION CONTROL; KIDNEY FAILURE, CHRONIC; OSTEOPOROSIS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS;

EID: 11244330547     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000151609.60618.3C     Document Type: Review

References (81)

1. Taylor DO, Edwards LB, Mohacsi PJ, Boucek MM, Trulock EP, Keck BM, Hertz MI. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report - 2003. J Heart Lung Transplant. 2003;22:616-624.
2. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834.
3. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Boehmer JP, Brozena SC, Dec GW, Ventura HO, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors: Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17: 744-753.
4. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report - 1999. J Heart Lung Transplant. 1999;18:611-626.
5. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimer W. Survival of heart transplant recipients with cyclosporine-induced renal insufficiency. Transplant Proc. 1998;30:1122-1123.
6. Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, Keck BM. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report - 2002. J Heart Lung Transplant. 2002;21:950-970.
7. Benza RL, Zoghbi GJ, Tallaj J, Brown R, Kirklin JK, Hubbard M, Rayburn B, Foley B, McGiffin DC, Pinderski LJ, Misra V, Bourge RC. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol. 2004;43:1973-1981.
8. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes arter cardiac transplantation. N Engl J Med. 1995;333:621-627.
9. Wenke K, Meiser B, Thiery J, Nagel D, von Scheldt W, Steinbeck G, Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96: 1398-1402.
10. Wenke K, Meiser B, Thiery J, Nagel D, von Scheldt W, Krobot K, Steinbeck G, Seidel D, Reichart B. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93-97.
11. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol. 1990; 65:106-111.
12. Frohlich ED, Ventura HO, Ochsner JL. Arterial hypertension after orthotopic cardiac transplantation. J Am Coll Cardiol. 1990;15:1102-1103.
13. Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med. 1988;85:131-133.
14. Pham SM, Kormos RL, Kawai A, Murali S, Hauler BG, Demetris AJ, Griffith BP. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc. 1996;28:1002-1004.
15. Radermacher J, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transpl Int. 1998;11:3-10.
16. Macleod AM, Thomson AW. FK 506: an immunosuppressantforthe 1990s? Lancet. 1991;337:25-27.
17. Reeves RA, Shapiro AP, Thompson ME, Johnsen AM. Loss of nocturnal decline in blood pressure after cardiac transplantation. Circulation. 1986;73: 401-408.
18. Wenting GJ, vd Meiracker AH, Simoons ML, Bos E, Ritsema v Eck HJ, Man in't Veld AJ, Weimar W, Schalekamp MA. Circadian variation of heart rate but not of blood pressure after heart transplantation. Transplant Proc. 1987; 19:2554-2555.
19. Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clin Transplant. 2001;15: 426-431.
20. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl. 1998;68:S130-S134.
21. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension. 1995;26:436-444.
22. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int. 1993;43:419-425.
23. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension. 1999;33:862-868.
24. Brozena SC, Johnson MR, Ventura H, Hobbs R, Miller L, Olivari MT, Clemson B, Bourge R, Quigg R, Mills RM Jr, Naftel D. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation: results of a prospective, randomized multicenter trial. J Am Coll Cardiol. 1996;27:1707-1712.
25. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164-170.
26. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy. 2003;23:788-801.
27. Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, Lachno DR, Cappuccio FP, Murday A, Yacoub MH, MacGregor GA. Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients: implications for the control of sodium balance. Circulation. 1994;89:1153-1159.
28. Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. Nephrol Dial Transplant. 1999;14:521-523.
29. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
30. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients: Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515.
31. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant. 1992;11:S124-S132.
32. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM Jr. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992;19:1315-1321.
33. Akhlaghi F, Jackson CH, Parameshwar J, Sharpies LD, Trull AK. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation. 2002;73:1258-1264.
34. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847-858.
35. Taylor DO, Barr ML, Meiser BM, Pham SM, Mentzer RM, Gass AL. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant. 2001;20:734-738.
36. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 2000;19:529-537.
37. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, Milani RV, Lavie CJ. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol. 2002;40: 1609-1614.
38. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004; 147:956-965.
39. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post-transplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583-592.
40. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999;318: 1104-1107.
41. Moore R, Boucher A, Carter J, Kim SJ, Kiberd B, Loertscher R, Mongeau JG, Prasad GV, Vautour L. Diabetes mellitus in transplantation: 2002 consensus guidelines. Transplant Proc. 2003;35:1265-1270.
42. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
43. Zietse R, Balk AH, vd Dorpel MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol. 1994;14:1-5.
44. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation. 1997;63:664-668.
45. Shaddy RE, Hammond EH, Yowell RL. Immunohistochemical analysis of platelet-derived growth factor and basic fibroblast growth factor in cardiac biopsy and autopsy specimens of heart transplant patients. Am J Cardiol 1996;77:1210-1215.
46. Lurie KG, Billingham ME, Jamieson SW, Harrison DC, Reitz BA. Pathogenesis and prevention of graft arteriosclerosis in an experimental heart transplant model. Transplantation. 1981;31:41-47.
47. Griepp RB, Stinson EB, Bieber CP, Reitz BA, Copeland JG, Oyer PE, Shumway NE. Control of graft arteriosclerosis in human heart transplant recipients. Surgery. 1977;81:262-269.
48. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987; 19:19-25.
49. de Lorgeril M, Boissonnat P, Bizollon C. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation: lack of interaction with the lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol. 1992;43:161-165.
50. de Lorgeril M, Boissonnat P, Dureau G, Guidollet J, Renaud S. Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. Transplantation. 1993;55:1195-1196.
51. Uber PA, Mehra MR, Park MH, Scott RL. Clopidogrel and rhabdomyolysis after heart transplantation. J Heart Lung Transplant. 2003;22:107-108.
52. Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, Hammond EH, Bristow MR. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993;56:359-362.
53. Dummer JS. Pneumocystis carinii infections in transplant recipients. Semin Respir Infect. 1990;5:50-57.
54. Soave R. Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis. 2001;33(suppl 1):S26-S31.
55. Fox BC, Sollinger HW, Beizer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim- sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89:255-274.
56. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
57. Streblow DN, Kreklywich C, Yin Q, De La Melena VT, Corless CL, Smith PA, Brakebill C, Cook JW, Vink C, Bruggeman CA, Nelson JA, Orloff SL. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol. 2003;77:2182-2194.
58. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis. 1999;1:115-126.
59. Rubin R. Infection in the organ transplant recipient. In: Rubin RHYL, ed. Clinical Approach to Infection in the Compromised Host. 3rd ed. New York, NY: Plenum; 2003.
60. Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med. 1978;298:951-953.
61. Wagle AM, Biswas J, Gopal L, Madhavan HN. Clinical profile and immunological status of cytomegalovirus retinitis in organ transplant recipients. Indian J Ophthalmol. 2002;50:115-121.
62. Egan JJ, Carroll KB, Yonan N, Woodcock A, Crisp A. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J Heart Lung Transplant. 2002;21:460-466.
63. Paniagua MJ, Crespo-Leiro MG, De la Fuente L, Tabuyo T, Mosquera I, Canizares A, Naya C, Farina P, Juffe A, Castro-Beiras A. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir. Transplant Proc. 2002;34:69-70.
64. Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, Grimm M, Zuckermann A, Wolner E, Laufer G. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant. 2003;22:250-257.
65. Kahl LE, Thompson ME, Griffith BP. Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge. Am J Med. 1989;87:289-294.
66. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-979.
67. Cummins D, Sekar M, Haul O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996;61:1661-1662.
68. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
69. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104:459-469.
70. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med. 1993;94:257-264.
71. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, Mancini DM, DiSesa VJ, Attie MF. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35-41.
72. Muchmore JS, Cooper DK, Ye Y, Schlegel VT, Zuhdi N. Loss of vertebral bone density in heart transplant patients. Transplant Proc. 1991;23: 1184-1185.
73. Berguer DG, Krieg MA, Thiebaud D, Burckhardt P, Stumpe F, Hurni M, Sadeghi H, Kappenberger L, Goy JJ. Osteoporosis in heart transplant recipients: a longitudinal study. Transplant Proc. 1994;26:2649-2651.
74. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int. 2000;57:684-690.
75. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
76. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int. 1995;57:15-19.
77. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350:767-776.
78. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271-292.
79. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum. 1996;39:1791-1801.
80. Dew MA, Kormos RL, DiMartini AF, Switzer GE, Schulberg HC, Roth LH, Griffith BP. Prevalence and risk of depression and anxiety-related disorders during the first three years after heart transplantation. Psychosomatics. 2001; 42:300-313.
81. Dobbels F, De Geest S, Cleemput JV, et al. Prevalence and correlates of depression after heart transplantation: a prospective, long-term study (>5 years post-HTX). J Heart Lung Transplant. 2002;21:151. Abstract.